-
公开(公告)号：US12011469B2
公开(公告)日：2024-06-18
申请号：US15987729
申请日：2018-05-23
申请人： Vireo Systems, Inc.
发明人： Mark C. Faulkner , Deeannah Seymour
IPC分类号： A61K35/747 , A61K9/00 , A61K9/02 , A61K9/48 , A61K31/702 , A61K33/22 , A61P31/10 , A61K47/02
CPC分类号： A61K35/747 , A61K9/0034 , A61K9/02 , A61K9/48 , A61K9/4825 , A61K9/485 , A61K9/4858 , A61K31/702 , A61K33/22 , A61P31/10 , A61K47/02
摘要： A parenteral delivery device and method of delivering a multi-system treatment to a centralized location where the delivery device includes at least an inner compartment encapsulating a first system and an outer compartment encapsulating a second system and the first and second systems have different mechanisms of action for use in the treatment of vaginal infection.
-
公开(公告)号：US20220218644A1
公开(公告)日：2022-07-14
申请号：US17582595
申请日：2022-01-24
申请人： Vireo Systems, Inc.
IPC分类号： A61K31/221 , A61K45/06 , A61K31/22
摘要： A method and composition for treating osteoarthritis including administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate. Ethyl (α-guanido-methyl) ethanoate provides a safe, non-toxic anti-inflammatory treatment for osteoarthritis.
-
公开(公告)号：US20220160671A1
公开(公告)日：2022-05-26
申请号：US17533528
申请日：2021-11-23
申请人： Vireo Systems, Inc.
发明人： Mark C. Faulkner , Donald W. Miller
IPC分类号： A61K31/215 , A61P31/12 , A61K45/06
摘要： Antiviral therapeutic compounds and compositions that may be used in methods of preventing and/or treating infection(s) caused by coronaviruses or influenza viruses.
-
公开(公告)号：US20210205250A1
公开(公告)日：2021-07-08
申请号：US17140733
申请日：2021-01-04
IPC分类号： A61K31/198 , A23L33/10 , A23L33/175 , A61K31/195 , A61K31/661 , A23K20/105 , A23K20/142 , A23K50/10 , A23L2/52 , A61K31/185 , A23K20/10 , A61K9/00
摘要： The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.
-
公开(公告)号：US20180250254A1
公开(公告)日：2018-09-06
申请号：US15968858
申请日：2018-05-02
IPC分类号： A61K31/198 , A23K50/10 , A61K31/195 , A61K31/185 , A61K9/00 , A61K31/661 , A23K20/10 , A23K20/142 , A23L33/175 , A23L33/10 , A23K20/105 , A23L2/52 , A23P10/40
CPC分类号： A61K31/198 , A23K20/10 , A23K20/105 , A23K20/142 , A23K50/10 , A23L2/52 , A23L33/10 , A23L33/175 , A23P10/40 , A23V2002/00 , A61K9/0053 , A61K31/185 , A61K31/195 , A61K31/661 , A23V2250/306 , A23V2200/33 , A23V2200/316
摘要： The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.
-
公开(公告)号：US08962685B2
公开(公告)日：2015-02-24
申请号：US13740909
申请日：2013-01-14
IPC分类号： A61K31/195
CPC分类号： A61K31/198 , A23K20/10 , A23K20/105 , A23K20/142 , A23K50/10 , A23L2/52 , A23L33/10 , A23L33/175 , A23P10/40 , A23V2002/00 , A61K9/0053 , A61K31/185 , A61K31/195 , A61K31/661 , A23V2250/306 , A23V2200/33 , A23V2200/316
摘要： The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.
摘要翻译： 本发明涉及第三代肌酸，特别是肌酸盐酸盐，其由于其增强的生物可利用性而促进肌肉发育和恢复的显着改善，同时与以前的肌酸形式相比，引起较少的负面副作用。
-
公开(公告)号：US12109195B2
公开(公告)日：2024-10-08
申请号：US17363193
申请日：2021-06-30
申请人： Vireo Systems, Inc.
发明人： Mark C. Faulkner , Deeannah Seymour
IPC分类号： A61K31/41 , A61K9/00 , A61K9/02 , A61K31/194 , A61K31/4168 , A61K31/7016 , A61K31/702 , A61K31/733 , A61K33/22 , A61K35/747 , A61P31/04
CPC分类号： A61K31/4168 , A61K9/0036 , A61K9/02 , A61K31/194 , A61K31/7016 , A61K31/702 , A61K31/733 , A61K33/22 , A61K35/747 , A61P31/04
摘要： Compositions and methods for treatment and prevention of vaginal infections where the compositions include creatinine, such as protonated creatinine or creatinine salts, and optionally one or more weak acids, such as boric acid. The compositions may be used to treat and/or prevent a vaginal infection, such as bacterial vaginosis, to prevent recurrence of a vaginal infection, to treat and/or prevent a sexually transmitted disease (STD) or sexually transmitted infection (STI), and reduce the incidence and/or risk of a subject transmitting a STI or STD.
-
公开(公告)号：US11826334B2
公开(公告)日：2023-11-28
申请号：US17533528
申请日：2021-11-23
申请人： Vireo Systems, Inc.
发明人： Mark C. Faulkner , Donald W. Miller
IPC分类号： A61K31/215 , A61K45/06 , A61P31/12
CPC分类号： A61K31/215 , A61K45/06 , A61P31/12
摘要： Antiviral therapeutic compounds and compositions that may be used in methods of preventing and/or treating infection(s) caused by coronaviruses or influenza viruses.
-
公开(公告)号：US20230159442A1
公开(公告)日：2023-05-25
申请号：US17993532
申请日：2022-11-23
申请人： Vireo Systems, Inc.
IPC分类号： C07C279/16 , C07C211/63
CPC分类号： C07C279/16 , C07C211/63
摘要： Antiviral therapeutic compounds and compositions that may be used in methods of preventing and/or treating infection(s) caused by coronaviruses or influenza viruses. The present disclosure also relates to compounds for use in boosting cellular energy production and/or optimizing cellular energy homeostasis and incorporation of such compounds into compositions for administration. Also disclosed are methods of boosting cellular energy production and/or optimizing cellular energy homeostasis.
-
公开(公告)号：US20210401806A1
公开(公告)日：2021-12-30
申请号：US17363193
申请日：2021-06-30
申请人： Vireo Systems, Inc.
发明人： Mark C. Faulkner , Deeannah Seymour
IPC分类号： A61K31/4168 , A61P31/04 , A61K33/22 , A61K31/194 , A61K9/02 , A61K9/00 , A61K35/747 , A61K31/702 , A61K31/733 , A61K31/7016
摘要： The present invention generally relates to compositions and methods for treatment and prevention of vaginal infections. More particularly, the present invention relates to compositions including creatinine, such as protonated creatinine or creatinine salts, and optionally one or more weak acids, such as boric acid. The disclosed compositions may be used to treat and/or prevent a vaginal infection, such as bacterial vaginosis, to prevent recurrence of a vaginal infection, to treat and/or prevent a sexually transmitted disease (STD) or sexually transmitted infection (STI), and reduce the incidence and/or risk of a subject transmitting a STI or STD.
-
-
-
-
-
-
-
-
-
搜索结果
34 条记录 (耗时 0.016 秒)
